葡萄糖转运蛋白1和葡萄糖转运蛋白4在多囊卵巢综合征中的研究进展OA

Polycystic ovary syndrome(PCOS)is a common endocrine disorder characterized by hyperandrogenism,obesity,and other symptoms,often leading to female infertility,menstrual irregularities,and metabolic dysregulation.Numerous studies have demonstrated that glucose metabolism disorders and the resulting insulin resistance play a significant role in the pathogenesis and progression of PCOS.Glucose transporter 1(GLUT1)and glucose transporter 4(GLUT4)are the most critical and extensively studied proteins in the glucose transporter family,involved in various physiological processes such as glucose uptake and metabolism.Recent research has shown that glucose transporters play a pivotal role in the pathogenesis of PCOS,particularly in the development of insulin resistance and metabolic abnormalities.GLUT1 is primarily expressed on the cell membrane and participates in basal glucose transport,while GLUT4 regulates its membrane expression and activity via insulin,thereby promoting glucose absorption.Studies indicate that abnormal expression of GLUT1 and GLUT4 in PCOS patients is closely associated with insulin resistance,glucose metabolism disorders,and weight gain.Clinically,various traditional Chinese medicine formulas and monomers targeting GLUT4 have been identified to improve PCOS.This article systematically reviews the research progress on GLUT1 and GLUT4 in PCOS,summarizes advancements in drugs targeting GLUT4 to treat PCOS,explores their role in insulin signaling pathways,and discusses their potential as therapeutic targets.These findings provide theoretical support for deepening the understanding of PCOS pathogenesis and developing novel diagnostic and therapeutic strategies.